Evidence map›Paper›PMID 42368460›Full record

ReviewFrontiers in cell and developmental biology2026

GDI2 protein: research progress and its mechanisms in diseases.

Changjian He, Tian He, Zan Zuo, Chao Yang, Yudan Zhang, Guanqi Su, Yunjiao Gong, Ping Wan, Wen Zhang

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Changjian He *Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, China.
Tian He *Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, China.
Zan Zuo *Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, China.
Chao YangDepartment of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, China.
Yudan ZhangDepartment of Gastroenterology, The First People's Hospital of Yunnan Province, School of Medicine, Kunming University of Science and Technology Affiliated Hospital, Kunming, China.
Guanqi SuDepartment of Gastroenterology, The First People's Hospital of Yunnan Province, School of Medicine, Kunming University of Science and Technology Affiliated Hospital, Kunming, China.
Yunjiao GongDepartment of Gastroenterology, The First People's Hospital of Yunnan Province, School of Medicine, Kunming University of Science and Technology Affiliated Hospital, Kunming, China.
Ping WanDepartment of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, China.
Wen ZhangDepartment of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GDP dissociation inhibitor 2 (GDI2), also termed RabGDIβ, is an evolutionarily conserved Rab GDP dissociation inhibitor that is broadly expressed across species and is required for fundamental cellular functions. Mechanistically, GDI2 controls the cycling of Rab small GTPases between membranes and the cytosol, thereby regulating Rab-dependent membrane targeting, intracellular trafficking, and downstream signal transduction. Increasing evidence indicates that GDI2 is not only a constitutive component of the membrane-transport machinery; aberrant GDI2 expression or activity is associated with diverse human diseases. Notably, the functional consequences of GDI2 dysregulation appear to be context dependent, with reported involvement in cancer, neurodegeneration, immune dysregulation, and metabolic disease. Here, we synthesize current knowledge of GDI2 biology, highlighting recent advances that delineate its molecular features and its roles in maintaining membrane-trafficking homeostasis, remodeling signaling networks, and shaping disease-relevant cellular phenotypes. We also discuss the translational implications of GDI2 as a potential diagnostic biomarker and therapeutic target, and we propose a conceptual framework to guide mechanistic interpretation and the development of GDI2-directed therapeutic strategies.

Indexed as

cancer-related regulationendocrine metabolismGDP dissociation inhibitor 2 (GDI2)infection immunityneurodegenerative diseasespharmacological modulationrab GTPases

Identifiers

PMID42368460
PMCPMC13303518

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.